Epidemiology of bacterial infections. Research on pathogenesis and molecular basis of antimicrobial resistance

Summary

This group’s research covers various lines of clinical and microbiological research, and includes multiple-antibiotic-resistant bacterial infectious, which are a large cause of morbidity and mortality. The study of risk factors and clinical characteristics in hospital-acquired infections, as well as the knowledge of genotypes, virulence factors and mechanisms of antibiotic resistance of bacterial pathogens, are essential for controlling epidemic outbreaks due to multi-resistant bacteria.

758 Publications

Strategic lines

Clinical and molecular epidemiology of pneumococcal disease
Clinical and molecular epidemiology of bacteraemia/sepsis
Clinical and molecular epidemiology of methicillin-resistant S. aureus infections.
Dynamic of microbial populations in exacerbations of chronic obstructive pulmonary disease.
Molecular characterisation of invasive strains of S. pyogenes.
Antimicrobial resistance: phenotype characterisation and study of molecular bases.
New techniques in microbiological diagnosis.
Application of atomic force microscopy in the study of oral biofilm.

Selected Publications

Abelenda Alonso,G;Calatayud,L;Rombauts,A;Meije,Y;Oriol,I;Sopena,N;Padulles,A et al, Multiplex real-time PCR in non-invasive respiratory samples to reduce antibiotic use in community-acquired pneumonia: a randomised trial, Nat Commun, 2024;15(1):7098-7098, doi:10.1038/s41467-024-51547-8
Pérez García,C;Sempere,J;de Miguel,S;Hita,S;Ubeda,A;Vidal,EJ;Llorente,J et al, Surveillance of invasive pneumococcal disease in Spain exploring the impact of the COVID-19 pandemic (2019-2023), J. Infect., 2024;89(2):106204-106204, doi:10.1016/j.jinf.2024.106204
Calvo Silveria,S;González Díaz,A;Grau,I;Marimón,JM;Cercenado,E;Quesada,MD;Casabella,A et al, Evolution of invasive pneumococcal disease by serotype 3 in adults: a Spanish three-decade retrospective study, Lancet Reg. Health-Eur., 2024;41100913-100913, doi:10.1016/j.lanepe.2024.100913
Paniagua García,M;Bravo Ferrer,JM;Pérez Galera,S;Kostyanev,T;de Kraker,M;Feifel,J;Palacios Baena,ZR et al, Attributable mortality of infections caused by carbapenem-resistant Enterobacterales: results from a prospective, multinational case-control-control matched cohorts study (EURECA), Clin. Microbiol. Infect., 2024;30(2):223-230, doi:10.1016/j.cmi.2023.11.008
Calvo Silveria,S;González Díaz,A;Marimón,J;Cercenado,E;Quesada,MD;Casabella,A;Larrosa,N et al, Resilience and emergence of pneumococcal serotypes and lineages in adults post-PCV13 in Spain: A multicentre study, J. Infect. Public Health, 2024;18(1):102619-102619, doi:10.1016/j.jiph.2024.102619

Selected Projects

2023-507293-40-00. A PHASE 4 STUDY USING A TEST-NEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE AGAINST VACCINE-TYPE RADIOLOGICALLY-CONFIRMED COMMUNITY-ACQUIRED PNEUMONIA IN ADULTS ≥65 YEARS OF AGE. Pfizer Inc. Budget: 162.540€. 2024- . PI: MARIA CARMEN ARDANUY TISAIRE.
PI21/01000. Una perspectiva global de las enfermedades neumocócicas y la resistencia en tiempos de pandemia por COVID-19 y vacunación universal en pediatría. Instituto de Salud Carlos III (ISCIII). Budget: 91.960€. 2022-2025. PI: ARDANUY TISAIRE, MARIA CARMEN.
CP19/00096. CONTRATOS MIGUEL SERVET – ISCIII. Instituto de Salud Carlos III (ISCIII). Budget: 130.155,12€. 2024-2025. PI: MARTI MARTI, SARA.
PI24/01378. Explorando la colonización y los serotipos de Streptococcus pneumoniae en adultos de riesgo: Implicaciones para la vacunación. Instituto de Salud Carlos III (ISCIII). Budget: 70.000€. 2025-2027. PI: CAMARA MAS, JORDI.
101113109. RELECOV 2.0: Consolidation of WGS and RT-PCR activities for SARS-CoV-2 in Spain towards sustainable use and integration of enhanced infrastructure and capacities in the RELECOV network (101113109). COMISSIÓ EUROPEA. Budget: 26.405,12€. 2023-2028. PI: DOMINGUEZ LUZON, MARIA ANGELES.